Olema Pharmaceuticals Reports Strong Cash Position, Advances Multiple Clinical Trials
OLMA has more than doubled off its 52-week low of $2.86.
Summary
Olema Pharmaceuticals reported full-year 2025 results, showcasing a strong $505.4 million cash balance and significant progress across its clinical pipeline, including upcoming data readouts for key drug candidates.
Key Events · Earnings and Guidance · OLMA
-
Strong Year-End Cash Position
Olema ended 2025 with $505.4 million in cash, cash equivalents, and marketable securities, bolstered by a $218.5 million public offering in November 2025.
-
Pivotal Phase 3 Trials Advancing
The company is on track to report top-line data in Fall 2026 from the Phase 3 OPERA-01 trial and has advanced enrollment in the OPERA-02 trial for palazestrant.
-
New Combination Study Initiated
A Phase 1b/2 study of palazestrant in combination with Pfizer's atirmociclib has been initiated.
-
Upcoming Clinical Data Readouts
Initial clinical data for OP-3136 is expected in Q2 2026, and top-line data from the OPERA-01 trial is anticipated in Fall 2026.
Analysis · OLMA · Life Sciences
Olema Pharmaceuticals reported its full-year 2025 financial and operational results, highlighting a robust cash position of $505.4 million, significantly strengthened by a $218.5 million public offering in November 2025. This capital provides a substantial runway to fund ongoing operations and advance its pipeline. The company also provided positive updates on its clinical programs, including continued enrollment in pivotal Phase 3 trials for palazestrant and the initiation of a new Phase 1b/2 study with Pfizer. Upcoming catalysts include initial clinical data for OP-3136 in Q2 2026 and top-line data from the OPERA-01 trial in Fall 2026, which are critical milestones for the company's valuation and future prospects.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OLMA was trading at $14.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.86 to $36.26. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.